Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported third-quarter 2019 earnings of $2.79 per share, vs. $2.47 per share expected. Revenues grew 23% to
Alexion Pharmaceuticals, (ALXN): Q3 2019 Earnings Snapshot
Categories
Health Care
Boston Scientific (BSX) Q3 earnings beat on 13% sales growth; stock gains
Earnings of medical device maker Boston Scientific Corporation (NYSE: BSX) increased and topped expectations in the third quarter, aided by a 13%
Eli Lilly beats Q3 earnings expectations; revenues miss estimates
Eli Lilly and Company (NYSE: LLY) surpassed earnings expectations for the third quarter of 2019 but revenues came in shy of estimates.
Thermo Fisher Scientific (TMO): Q3 2019 Earnings Snapshot
-- Thermo Fisher Scientific (NYSE: TMO) reported third-quarter 2019 earnings of $2.94 per share, vs. $2.87 per share expected. -- Revenues grew
Anthem (ANTM): Q3 2019 Earnings Snapshot
-- Anthem Inc. (NYSE: ANTM) reported Q3 2019 earnings of $4.87 per share, vs. $4.82 expected. -- Revenues grew 15% to
Biogen (BIIB) Q3 profit rises 7% on spinal muscular atrophy drug addition
Biogen Inc. (NASDAQ: BIIB) reported a 7% increase in earnings for the third quarter of 2019 as spinal muscular atrophy drug Spinraza
Quest Diagnostics (DGX) Q3 2019 Earnings Snapshot
-- Quest Diagnostics (NYSE: DGX) reported third quarter 2019 adjusted EPS of $1.76 vs. $1.71 expected. Check below Quest Diagnostics Q3 2019
Centene (CNC): Q3 2019 Earnings Snapshot
Centene Corporation (NYSE: CNC) reported third-quarter 2019 adjusted earnings of $0.96 per share versus $0.95 per share expected. Total revenues grew by
PetMed Express (PETS) Q2 profit dips 38% but beats estimates
PetMed Express Inc. (NASDAQ: PETS) reported a 38% dip in earnings for the second quarter of 2020 due to lower sales and
Biogen (BIIB) earnings preview: Will stock bounce back after Q3 report?
The market value of pharma giant Biogen, Inc. (NASDAQ: BIIB) declined by a third in March when the stock suffered a heavy
Intuitive Surgical’s Q3 results surpass expectations
Intuitive Surgical (NASDAQ: ISRG) beat revenue and earnings expectations for the third quarter of 2019, sending the shares climbing 4.4% in aftermarket
PetMed Express on a rough patch ahead of next week’s Q2 earnings report
PetMed Express (NASDAQ: PETS) is set to report its second-quarter earnings results on Monday, October 21, before the market opens. The pet
Abbott Laboratories (ABT) reports in-line earnings for Q3; sales miss view
Abbott Laboratories' (NYSE: ABT) third quarter 2019 earnings came in line with the market's projections, while sales missed the expectations. The pharma
Johnson & Johnson (JNJ) Q3 earnings, sales beat Street view; stock gains
Earnings of healthcare conglomerate Johnson & Johnson (NYSE: JNJ) increased and topped the Street view in the third quarter helped by a
UnitedHealth Group’s Q3 results surpass expectations
UnitedHealth Group (NYSE: UNH) topped market expectations for revenue and earnings in the third quarter of 2019, allowing the stock to gain
Can Intuitive Surgical (ISRG) thrive on the health of da Vinci system in Q3?
Intuitive Surgical (NASDAQ: ISRG), a market leader in robotic-assisted surgical systems, continues to scale new heights aided by the success of its
Rite Aid (RAD) recovers on optimistic future after a lackluster run
Rite Aid Corporation (NYSE: RAD) stock opened higher on Friday and is recovering from the multi-year low on August 15. Investors turned
Abbott Laboratories: Solid product line expected to boost Q3 results
There are few pharmaceutical companies as solid as Abbott Laboratories (NYSE: ABT). Thanks to the two major acquisitions it made a couple
Johnson & Johnson (JNJ) likely to feel the pinch in Q3
Johnson & Johnson (NYSE: JNJ) is slated to release its third-quarter earnings results on Tuesday, October 15, before the market opens. The
What to expect when UnitedHealth reports Q3 earnings
UnitedHealth Group (NYSE: UNH) is scheduled to report third quarter 2019 earnings on Tuesday, October 15, before the market opens. Analysts forecast
SmileDirectClub stock hits its lowest since IPO amid analyst initiations
SmileDirectClub (NASDAQ: SDC) stock has fallen 32% to $11.20 on Tuesday, which is the teledentistry company's lowest since the initial public offering